Raising questions about antidepressants

Psychotherapy and Psychosomatics

Volumn 68, Issue 1, 1999, Pages 3-14

  Antonuccio, David O ^a   Danton, William G ^a   DeNelsky, Garland Y ^b   Greenberg, Roger P ^c   Gordon, James S ^d  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^d The Center for Mind Body Medicine   (United States)

Author keywords

Antidepressant drugs; Cognitive behavioral psychotherapy; Depressive disorder; Long term outcome; Placebo effect; Randomized control trials

Indexed keywords

ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER;

ARTICLE; BEHAVIOR THERAPY; COGNITIVE THERAPY; DEPRESSION; DRUG EFFICACY; HUMAN; MEDICAL RESEARCH; PSYCHOTHERAPY; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; BIAS (EPIDEMIOLOGY); CHILD; CONFLICT OF INTEREST; DEPRESSIVE DISORDER; DRUG EVALUATION; DRUG THERAPY, COMBINATION; ECONOMICS, PHARMACEUTICAL; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; META-ANALYSIS; PUBLISHING; REPRODUCIBILITY OF RESULTS; RESEARCH;

EID: 0032959972     PISSN: 00333190     EISSN: None     Source Type: Journal    
DOI: 10.1159/000012304     Document Type: Article

References (162)

1. Amenson CS, Lewinsohn PM: An investigation into the observed sex difference in prevalence of unipolar depression. J Abnorm Psychol 1981;90:1-13.
2. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen H, Kendler KS: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994;51: 8-19.
3. Oliver JM, Simmons ME: Affective disorders and depression as measured by the diagnostic interview schedule and the Beck Depression Inventory in an unselected adult population. J Clin Psychol 1985;41:469-477.
4. Narrow WE, Regier DA, Rae DS, Manderscheid RW. Locke BZ: Use of services by persons with mental and addictive disorders: Findings from the National Institute of Mental Health Epidemiological Catchment Area Program. Arch Gen Psychiatry 1993;50:95-107.
5. Olfson MD, Klerman GL: Trends in the prescription of antidepressants by office-based psychiatrists. Arch Gen Psychiatry 1993;150: 571-577.
6. Kramer P: Listening to Prozac. New York, Viking, 1993.
7. Davis JM, Wang Z, Janicak PG: A quantitative analysis of clinical drug trials for the treatment of affective disorders. Psychopharmacol Bull 1993;29:175-181.
8. Joffe R, Sokolov S, Streiner D: Antidepressant treatment of depression: A meta-analysis. Can J Psychiatry 1996;41:613-616.
9. Morris JB, Beck AT: The efficacy of antidepressant drugs: A review of research (1958 to 1972). Arch Gen Psychiatry 1974;30:667-674.
10. Quality Assurance Project: A treatment outline for depressive disorders. Aust NZ J Psychiatry 1983;17:129-146.
11. Song F, Freemantle N, Sheldon TA, House A, Watson, Long A, Mason J: Selective serotonin reuptake inhibitors: Meta-analysis of efficacy and acceptability. BMJ 1993;306:683-687.
12. Ioannidis JPA: Effects of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA 1998;279:281-286.
13. Jadad AR, Rennie D: A randomized controlled trial gets a middle-aged checkup. JAMA 1998; 279:319-320.
14. Greenberg RP, Fisher S: Examining antidepressant effectiveness: Findings, ambiguities, and some vexing puzzles; in Fisher S, Greenberg RP (eds): The Limits of Biological Treatments for Psychological Distress: Comparisons with Psychotherapy and Placebo. Hillsdale, Erlbaum, 1989, pp 1-37.
15. Rosenthal R: The 'file drawer problem' and tolerance for null results. Psychol Bull 1979;86: 638-641.
16. Pushing drugs to doctors: Consumer Reports 1992, February, pp 87-94.
17. Gram LF: Fluoxetine. N Engl J Med 1994;331: 1354-1361.
18. Campbell EG, Louis KS, Blumenthal D: Looking a gift horse in the mouth: Corporate gifts supporting life sciences research. JAMA 1998; 279:995-999.
19. Cho MK, Bero LA: The quality of drug studies published in symposium proceedings. Ann Intern Med 1996;124:485-489.
20. Stelfox HT, Chua G, O'Rourke K, Detsky AS: Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med 1998;338: 101-106.
21. Blumenthal D, Campbell EG, Anderson MS, Causino N, Louis KS: Withholding research results in academic life science: Evidence from a national survey of faculty. JAMA 1997;277: 1224-1228.
22. Loebel AD, Hyde TS, Dunner DL: Early placebo response in anxious and depressed patients. J Clin Psychiatry 1986;47:230-233.
23. Sommers-Flanagan J, Sommers-Flanagan R: Efficacy of antidepressant medication with depressed youth: What psychologists should know. Pro Psychol Res Prac 1996;27:145-153.
24. Greenberg RP, Fisher S, Riter JR: Placebo washout is not a meaningful part of antidepressant drug trials. Percept Mot Skills 1995;81: 688-690.
25. Trivedi MH, Rush J: Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications? Neuropsychopharmacology 1994;11:33-43.
26. Brown WA: Placebo as a treatment for depression. Neuropsychopharmacology 1984;10: 265-269.
27. Greenberg RP, Fisher S: Mood-mending medicines: Probing drug, psychotherapy, and placebo solutions; in Fisher S, Greenberg RP (eds): From Placebo to Panacea: Putting Psychiatric Drugs to the Test. New York, Wiley & Sons, 1997. pp 115-172.
28. Hughes JR, Krahn D: Blindness and the validity of the double-blind procedure. J Clin Psychopharmacol 1985;5:138-142.
29. Margraf J, Ehlers A, Roth WT, Clark DB, Sheikh J, Agras WS, Taylor CB: How 'blind' are double-blind studies? J Consult Clin Psychol 1991;59:184-187.
30. Schulz KF, Chalmers I, Hayes RJ, Altman DG: Empirical evidence of bias: Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-412.
31. Carroll KM, Rounsaville BJ, Nich C: Blind man's bluff: Effectiveness and significance of psychotherapy and pharmacotherapy blinding procedures in a clinical trial. J Consult Clin Psychol 1994;62:276-280.
32. Thomson R. Side effects and placebo amplification. Br J Psychiatry 1982;140:64-68.
33. Moncrieff J, Wessely S, Hardy R: Meta-analysis of trials comparing antidepressants with active placebos. Br J Psychiatry 1998;172:227-231.
34. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;12:56-62.
35. Endicott J, Spitzer RL, Fleiss JL, Cohen J: The Global Assessment Scale: A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976;33:766-771.
36. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571.
37. Lambert MJ, Hatch DR, Kingston MD, Edwards BC: Zung, Beck, and Hamilton rating scales as measures of treatment outcome: A meta-analytic comparison. J Consult Clin Psychol 1986;54:54-59.
38. Murray EJ: Measurement issues in the evaluation of pharmacological therapy; in Fisher S, Greenberg RP (eds): The Limits of Biological Treatments for Psychological Distress: Comparisons with Psychotherapy and Placebo. Hillsdale, Erlbaum, 1989, pp 39-67.
39. Greenberg RP, Bornstein RF, Greenberg MD, Fisher S: A meta-analysis of antidepressant outcome under 'blinder' conditions. J Consult Clin Psychol 1992;60:664-669.
40. Greenberg RP, Bornstein RF, Zborowski MJ, Fisher S, Greenberg MD: A meta-analysis of fluoxetine outcome in the treatment of depression. J Nerv Ment Dis 1994; 182:547-551.
41. Anderson IM, Tomenson BM: The efficacy of selective serotonin re-uptake inhibitors in depression: A meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 1994;8:238-249.
42. Brownell K, Stunkard A: The double-blind in danger: Untoward consequences of informed consent. Am J Psychiatry 1982;139:1487.
43. Ney PG, Collins C, Spensor C: Double blind: Double talk or are there ways to do better research? Med Hypotheses 1986;21:119-126.
44. Fisher S, Greenberg RP: How sound is the double-blind design for evaluating psychotropic drugs? J Nerv Ment Dis 1993;181:345-350.
45. Basoglu M, Marks I, Livanou M, Swinson R: Double blindness procedures, rater blindness, and ratings of outcome: Observations from a controlled trial. Arch Gen Psychiatry 1997;54: 744-748.
46. Bystritsky A, Waikar SV: Inert placebo versus active medication: Patient blindability in clinical pharmacological trials. J Nerv Ment Dis 1994;182:485-487.
47. White K, Kando J, Park T, Waternaux C, Brown WA: Side effects and the 'blindability' of clinical drug trials. Clin Res Reports 1992; 149:1730-1731.
48. Rabkin JG, Markowitz JS, Stewart J, McGrath P, Harrison, Quitkin FM, Klein DF: How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine. Psychiatry Res 1986;19:75-86.
49. Kirsch I, Sapperstein G: Listening to Prozac, but hearing placebo? A meta-analysis of antidepressant medication. Prev Treat; 1998;1:0002a; www:http://journals.apa.org/treatment.
50. Rickels K: Use of placebo in clinical trials. Psychopharmacol Bull 1986;22:19-24.
51. Hollon SD, DeRubeis RJ: Placebo-psychotherapy combinations: Inappropriate representations of psychotherapy in drug-psychotherapy comparative trials. Psychol Bull 1981; 90:467-477.
52. Ambrosini PJ, Bianchi MD, Rabinovich H, Elia J: Antidepressant treatments in children and adolescents. I. Affective disorders. J Am Acad Child Adolesc Psychiatry 1993;32:1-6.
53. Dujovne VF, Barnard MU, Rapoff MA: Pharmacological and cognitive-behavioral approaches in the treatment of childhood depression: A review and critique. Clin Psychol Rev 1995;15:589-611.
54. Fisher RL, Fisher S: Antidepressants for children: Is scientific support necessary? J Nerv Ment Dis 1995;184:99-102.
55. Fisher RL, Fisher S: Are we justified in treating children with psychotropic drugs? in Fisher S, Greenberg RP (eds): From Placebo to Panacea: Putting Psychiatric Drugs to the Test. New York, Wiley & Sons, 1997, pp 307-322.
56. Hazell P, O'Connell D, Heathcote D, Robertson J, Henry D: Efficacy of tricyclic drugs in treating child and adolescent depression: A meta-analysis. BMJ 1995;310:897-901.
57. Goleman D: Use of antidepressants in children at issue. New York Times 1993, December 15, C17.
58. Riddle MA, Geller B, Ryan N: Another sudden death in a child treated with desipramine. J Am Acad Child Adolesc Psychiatry 1993;9:283-289.
59. Simeon JG, Dinicola VF, Ferguson HB, Copping W: Adolescent depression: A placebo-controlled fluoxetine treatment study and follow-up. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:791-795.
60. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, Rintelmann J: A double-blind randomized placebo-controlled trial of fluoxetine in depressed children and adolescents. Arch Gen Psychiatry 1997;54: 1031-1037.
61. McElroy SL, Keck PE, Friedman LM: Minimizing and managing antidepressant side effects. J Clin Psychiatry 1995;56(suppl 2):49-55.
62. Settle EC: Antidepressant side effects: Issues and Options. J Clin Psychiatry Monogr 1992; 10:48-61.
63. Jefferson JW: Treatment of depressed patients who have become nontolerant to antidepressant medication because of cardiovascular side effects. J Clin Psychiatry Monogr 1992;10:66-71.
64. Moir DC, Crooks J, Cornwell WB, O'Malley K, Dingwall-Fordyce I, Turnbull MJ, Weir RD: Cardiotoxicity of amitriptyline. Lancet 1972; ii:561-564.
65. Seagraves RT: Sexual dysfunction complicating the treatment of depression. J Clin Psychiatry Monogr 1992;10:75-79.
66. Popkin MK, Callies AL, Mackenzie TB: The outcome of antidepressant use in the medically ill. Arch Gen Psychiatry 1985;41:469-477.
67. Halbreich U, Shen J, Panaro V: Are chronic psychiatric patients at increased risk for developing breast cancer? Am J Psychiatry 1996; 153:559-560.
68. Anderson IM, Tomenson BM: Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: A meta-analysis. BMJ 1995;310:1433-1438.
69. Nelson J: Are the SSRIs really better tolerated than the TCAs for treatment of major depression? Psychiatr Ann 1994;24:628-631.
70. Menting JEA, Honig A, Verhey FRJ, Harmans M, Rozendaal N, de Vet HCW, van Praag HM: Selective serotonin reuptake inhibitors (SSRIs) in the treatment of elderly depressed patients: A qualitative analysis of the literature on their efficacy and side-effects. Int Clin Psychopharmacol 1996;11:165-175.
71. Hotopf M, Hardy R, Lewis G: Discontinuation rates of SSRIs and tricyclic antidepressants: A meta-analysis and investigation of heterogeneity. Br J Psychiatry 1997;170:120-127.
72. Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC: Explicit criteria for determining inappropriate medication use in nursing homes. Arch Intern Med 1991;151: 1825-1832.
73. Kapur S, Mieczkowski T, Mann JJ: Antidepressant medication and the relative risk of suicide attempt and suicide. JAMA 1992;268: 3441-3445.
74. Kathol RG, Henn FA: Tricyclics: The most common agent used in potentially lethal overdoses. J Nerv Ment Dis 1982;171:250-252.
75. Nemcroff CB, DeVane CL, Pollock BG: Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-320.
76. Taylor D: Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination: Interactions and therapeutic uses. Br J Psychiatry 1995;167:575-580.
77. US Department of Health and Human Services: Annual Medical Examiner Data 1994: Data from the drug abuse warning network. DHHS Publication No. (SMA) 96-3078, 1996.
78. Rascati K: Drug utilization review of concomitant use of specific serotonin reuptake inhibitors or clomipramine with antianxiety/sleep medications. Clin Ther 1995;17:786-790.
79. Sturm R, Wells KB: How can care for depression become more cost-effective? JAMA 1995; 273:51-58.
80. Mills KC: Serotonin syndrome. Clin Pharm 1995;52:1475-1482.
81. Linden RD, Wilcox CS, Heiser JF, Cavanaugh E, Wisselink PG: Are selective serotonin reuptake inhibitors well tolerated in somaticizing depressives? Psychopharmacol Bull 1994;30: 151-156.
82. Gitlin MJ: Psychotropic medications and their effects on sexual dysfunction: Diagnosis, biology, and treatment approaches. J Clin Psychiatry 1994;55:406-413.
83. Modell JG, Katholi CR, Modell JD, DePalma RL: Comparative sexual side effects of buproprion, fluoxetine, paroxetine, and sertraline. Clin Pharmacol Ther 1997;61:476-487.
84. Pastuszak A, Schick-Boschetto B, Zuber C, Feldcamp M, Pinelli M, Sihn S, Donnenfeld A, McCormack M, Leen-Mitchell M, Woodland C, Gardner A, Horn M, Koren G: Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993;269:2246-2248.
85. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL: Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335:1010-1015.
86. Lenhoff M: Potential complications of fluoxetine. VA Practitioner 1994;11:33-41.
87. Leo RJ: Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996;57:449-454.
88. Teicher MH, Glod C, Cole J: Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990;147: 207-210.
89. Beasley CM, Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH, Heiligenstein JH, Thompson VL, Murphy DJ, Masica DN: Fluoxetine and suicide: A meta-analysis of controlled trials of treatment for depression. BMJ 1991;303:685-692.
90. Heiligenstein JH, Beasley CM, Potvin JH: Fluoxetine not associated with increased aggression in controlled clinical trials. Int Clin Psychopharmacol 1993;8:277-280.
91. Tollefson GD, Rampey AH, Beasley CM, Enas GG, Potvin JH: Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression. J Clin Psychopharmacol 1994;14:163-169.
92. Lemonick MD: The mood molecule. Time 1997, September 29, pp 75-82.
93. Dilsaver SC, Greden JF: Antidepressant withdrawal phenomena. Biol Psychiatry 1984;19:237-256.
94. Coupland NJ, Bell CJ, Potokar JP: Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996;16:356-362.
95. Koranyi ED: Morbidity and rate of undiagnosed physical illnesses in a psychiatric clinic population. Arch Gen Psychiatry 1979;36: 414-419.
96. Hall RC, Popkin MK, Devaul RA, Fallaice LA, Stickney SK: Physical illness presenting as psychiatric disease. Arch Gen Psychiatry 1978;35:1315-1320.
97. Gatz M, Pedersen NS, Plomin R, Nesselroade JR, McClearn GE: Importance of shared genes and shared environments for symptoms of depression in older adults. J Abnorm Psychol 1992;101:701-708.
98. Kendler KS, Kessler RC, Walter EE, MacLean C, Neale MC, Heath AC, Eaves LJ: Stressful life events, genetic liability, and onset of an episode of major depression in women. Am J Psychiatry 1995;152:833-842.
99. Kendler KS, Walters EE, Kessler RC: The prediction of length of major depressive episodes: Results from an epidemiological sample of female twins. Psychol Med 1997;27: 107-117.
100. Blehar MC, Weissman MM, Gershon ES, Hirschfeld RMA: Family and genetic studies of affective disorders. Arch Gen Psychiatry 1988;45:289-292.
101. Richelson E: Biological basis of depression and therapeutic relevance. J Clin Psychiatry 1991;52(suppl):4-10.
102. Higley JD, Suomi SJ, Linnoila M: A nonhuman primate model of type II alcoholism? 2. Diminished social competence and excessive aggression correlates with low cerebrospinal fluid 5-hydroxyindoleacetic acid concentrations. Alcohol Clin Exp Res 1996;20:643-650.
103. Hallman J, Oreland L: Serotonergic mechanisms and psychiatric disorders. Nord Psykiatr Tidsskr 1989;43:53-59.
104. Cooper JR, Bloom FE, Roth RH: The Biochemical Basis of Neuropharmacology. New York, Oxford University Press, 1996.
105. Tollefson GD: Selective serotonin reuptake inhibitors; in Schatzberg AF, Nemeroff CB (eds): The American Psychiatric Press Textbook of Psychopharmacology. Washington, American Psychiatric Press Inc., 1995, pp 161-182.
106. Fava GA: Holding on: Depression, sensitization by antidepressant drugs, and the prodigal experts. Psychother Psychosom 1995;64:57-61.
107. Fava GA: Do antidepressant and antianxiety drugs increase chronicity in affective disorders? Psychother Psychosom 1994;61:125-131.
108. Baldessarini RJ: Risks and implications of interrupting maintenance psychotropic drug therapy. Psychother Psychosom 1995;63: 137-141.
109. Meterissian GB, Bradwejn J: Comparative studies on the efficacy of psychotherapy, pharmacotherapy, and their combination in depression: Was adequate pharmacotherapy provided? J Clin Psychopharmacol 1989;9: 324-339.
110. Brugha TS, Bebbington PE, MacCarthy B, Sturt E, Wykes T: Antidepressants may not assist recovery in practice: A naturalistic prospective survey. Acta Psychiatr Scand 1992; 86:5-11.
111. Kocsis JH, Hanin I, Bowden C, Brunswick D: Imipramine and amitriptyline plasma concentrations and clinical response in major depression. Br J Psychiatry 1986;148:52-57.
112. Simpson BM, White KL, Boyd JL, Cooper TB, Halaris A, Wilson IC, Raman EJ, Ruther E: Relationship between plasma antidepressant levels and clinical outcome for inpatients receiving imipramine. Am J Psychiatry 1982; 139:358-360.
113. Amsterdam JD, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, Michelson D, Hornig-Rohan M, Beasley CM: Fluoxetine and norfluoxetine plasma concentrations in major depression: A multicenter study. Am J Psychiatry 1997;154:963-969.
114. Fava GA: The concept of recovery in affective disorders. Psychother Psychosom 1996; 65:2-13.
115. Ribeiro SCM, Tandon R, Grunhaus L, Greden JF: The DST as a predictor of outcome in depression: A meta-analysis. Am J Psychiatry 1993;150:1618-1629.
116. McKnight DL, Nelson-Gray RO, Barnhill J: Dexamethasone suppression test and response to cognitive therapy and antidepressant medication. Behav Ther 1992;23:99-111.
117. Thase ME, Buysee DJ, Frank E, Cherry CR, Cornes CL, Mallinger AG, Kupfer DJ: Which depressed patients will respond to interpersonal psychotherapy? The role of abnormal EEG sleep profiles. Am J Psychiatry 1997; 154:502-509.
118. Simons AD, Thase M: Biological markers, treatment outcome, and 1-year follow-up in endogenous depression: Electroencephalographic sleep studies and response to cognitive therapy. J Consult Clin Psychol 1992;60: 392-401.
119. Baxter LR, Schwartz JM, Bergman KS, Szuba MP, Guze BH, Mazziotta JC, Alazraki A, Selin CE, Ferng H, Munford P, Phelps ME: Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry 1992;49:681-689.
120. Blondi M: Beyond the brain-mind dichotomy and toward a common organizing principle of pharmacological and psychological treatments. Psychother Psychosom 1985;64:1-8.
121. Cappelleri JC, Ioannidis JPA, Schmid CH, de Ferranti SD, Aubert M, Chalmers TC, Lau J: Large trials vs meta-analysis of smaller trials: How do their results compare? JAMA 1996; 276:1332-1338.
122. LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F: Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997; 337:536-542.
123. Wilson GT, Rachman SJ: Meta-analysis and the evaluation of psychotherapy outcome: Limitations and liabilities. J Consult Clin Psychol 1983;51:54-64.
124. Hollon SD, Shelton RC, Loosen PT: Cognitive therapy and pharmacotherapy for depression. J Consult Clin Psychol 1991;59:88-99.
125. Robinson LA, Berman JS, Neimeyer RA: Psychotherapy for the treatment of depression: A comprehensive review of controlled outcome research. Psychol Bull 1990;108:30-49.
126. Dobson KS: A meta-analysis of the efficacy of cognitive therapy for depression. J Consult Clin Psychol 1989;57:414-419.
127. Steinbrueck SM, Maxwell SE, Howard GS: A meta-analysis of psychotherapy and drug therapy in the treatment of unipolar depression with adults. J Consult Clin Psychol 1983; 51:856-853.
128. Conte HR, Plutchik R, Wild KV, Karasu TB: Combined psychotherapy and pharmacotherapy for depression: A systematic analysis of the evidence. Arch Gen Psychiatry 1986;43: 471-479.
129. Wexler BE, Cicchetti DV: The outpatient treatment of depression: Implications of outcome research for clinical practice. J Nerv Ment Dis 1992;180:277-286.
130. Persons JB, Thase ME, Crits-Christoph P: The role of psychotherapy in the treatment of depression: Review of two practice guidelines. Arch Gen Psychiatry 1996;53:283-290.
131. Antonuccio DO, Danton WG, DeNelsky GY: Psychotherapy versus medication for depression: Challenging the conventional wisdom with data. Pro Psychol Res Pract 1995;26: 574-585.
132. Muñoz RF, Hollon SD, McGrath E, Rehm LP, Van den Bos GR: On the AHCPR depression in primary care guidelines: Further considerations for practitioners. Am Psychol 1994;49:42-61.
133. Abi-Karam A: Personal communication regarding cost-analysis at the Human Behavior Institute, 1997.
134. Fava M, Kaji J: Continuation and maintenance treatments of major depressive disorder. Psychiatr Ann 1994;24:281-290.
135. Frank E, Kupfer DJ, Perel JM, Cornes C, Jarrett DB, Mallinger AG, Thase ME, McEachran AB, Grochocinski VJ: Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47: 1093-1099.
136. Kupfer DJ, Frank E, Perel JM, Cornes C, Mallinger AG, Thase ME, McEachran AB, Grochocinski VJ: Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992;49:769-773.
137. Paykel ES, Dimascio A, Haskell D, Prusoff BA: Effects of maintenance amitriptyline and psychotherapy on symptoms of depression. Psychol Med 1975;5:67-77.
138. Reynolds CF, Frank E, Kupfer DJ, Thase ME, Perel JM, Mazumdar S, Houck PR: Treatment outcome in recurrent major depression: A post hoc comparison of elderly ('young old') and midlife patients. Am J Psychiatry 1996;153:1288-1292.
139. Reynolds CF, Frank E, Perel JM, Imber SD, Cornes C, Morycz RK, Mazumdar S, Miller MD, Pollock BG, Rifai AH, Stack JA, George CJ, Houck PR, Kupfer DJ: Combined pharmacotherapy and psychotherapy in the acute and continuation treatment of elderly patients with recurrent major depression: A preliminary report. Am J Psychiatry 1992;149: 1687-1692.
140. Frank E, Prien PF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, Rush AJ, Weissman MM: Conceptualization and rationale for consensus definitions of terms in major depressive disorder: Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991;48:851-855.
141. Antonuccio DO, Akins WT, Chatham PM, Monagin JA, Tearnan BH, Ziegler BL: An exploratory study: The psychoeducational group treatment of drug-refractory unipolar depression. J Behav Ther Exp Psychiatry 1984;15:309-313.
142. Fava GA, Savron G, Grandi S, Raffanelli C: Cognitive-behavioral management of drug-resistant major depressive disorder. J Clin Psychiatry 1997;58:278-282.
143. Fava GA, Grandi S, Zielezny M, Rafanelli C, Canestrari R: Four-year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry 1996;153:945-947.
144. Krupnick JL, Sotsky SM, Simmens S, Moyer J, Elkin I, Watkins J, Pilkonis PA: The role of therapeutic alliance in psychotherapy and pharmacotherapy outcome: Findings in the National Institute of Mental Health Treatment of Depression Collaborative Research Program. J Consult Clin Psychol 1996;64: 532-539.
145. Elkin I, Shea T, Watkins JT, Imber SD, Sotsky SM, Collins JF, Glass DR, Pilkonis PA, Leber WR, Docherty JP, Fiester SJ, Parloff MB: National Institute of Mental Health Treatment of Depression Collaborative Research Program: General effectiveness of treatments. Arch Gen Psychiatry 1989;46: 971-982.
146. Blatt SJ, Sanislow CA, Zuroff DC, Pilkonis PA: Characteristics of effective therapists: Further analyses of data from the National Institute of Mental Health Treatment of Depression Collaborative Research Program. J Consult Clin Psychol 1996;64:1276-1284.
147. Dunner DL, Schmaling KB, Hendrickson H, Becker J, Lehman A, Bea C: Cognitive therapy versus fluoxetine in the treatment of dysthymic disorder. Depression 1996;4:34-41.
148. Antonuccio DO, Lewinsohn PM, Steinmetz JL: Identification of therapist differences in a group treatment for depression. J Consult Clin Psychol 1982;50:433-435.
149. Free ML, Oei TPS, Sanders MR: Treatment outcome of a group cognitive therapy program for depression. Int J Group Psychother 1991;41:533-547.
150. Miller RC, Berman JS: The efficacy of cognitive behavior therapies: A quantitative review of the research evidence. Psychol Bull 1983; 94:39-53.
151. Brown RA, Lewinsohn PM: A psychoeducational approach to the treatment of depression: Comparison of group, individual, and minimal contact procedures. J Consult Clin Psychol 1984;52:774-783.
152. Cuijpers P: Bibliotherapy in unipolar depression: A meta-analysis. J Behav Ther Exp Psychiatry 1997;28:139-147.
153. Jamison C, Scogin F: The outcome of cognitive bibliotherapy with depressed adults. J Consult Clin Psychol 1995;63:644-650.
154. Smith NM, Floyd MR, Scogin F, Jamison CS: Three-year follow-up of bibliotherapy for depression. J Consult Clin Psychol 1997;65: 324-327.
155. Antonuccio DO, Thomas M, Danton WG: A cost-effectiveness analysis of cognitive behavior therapy and fluoxetine (Prozac) in the treatment of depression. Behav Ther 1997; 28:187-210.
156. Agency for Health Care Policy and Research: Depression is a treatable illness. USDHSS Publication No AHCPR 93-0553, April 1993.
157. American Psychiatric Association: Practice guidelines for major depressive disorder in adults. Am J Psychiatry 1993;150(suppl):1-26.
158. McIntyre JS: The role of psychotherapy in the treatment of depression: Review of two practice guidelines. Arch Gen Psychiatry 1996;53: 291-293.
159. Rush AJ: The role of psychotherapy in the treatment of depression: Review of two practice guidelines. Arch Gen Psychiatry 1996;53: 298-300.
160. Merriam AE, Karasu TB: The role of psychotherapy in the treatment of depression: Review of two practice guidelines. Arch Gen Psychiatry 1996;53:301-302.
161. Kocsis JH: Practice guidelines and professional challenges: What psychotherapists need to do. Arch Gen Psychiatry 1996;53: 303-304.
162. Gordon JS: Manifesto for a New Medicine: Your Guide to Healing Partnerships and the Wise Use of Alternative Therapies. New York, Addison-Wesley Publishing Co, 1996.